Cytodyn Inc (CYDY)

[kgromax]

A pure gem which was revealed by Nader Pourhassan the CEO in the October 20th conference call (see the Bloomberg screenshot below).

the trial DSMC requested the new 75% interim to, I quote Nader who himself read what they wrote during the conference call, "perform a sample size reassessment".

I am a statistician and a "sample size reassessment" is a very specific technical word that has zero ambiguity. It is very clear for any statistician so I will explain it for everybody here:
it means they wanted to reassess how many more patients would be necessary to be able to detect the Leronlimab effect hypothesized in the study's initial design. That is a bad thing, because if you start seeing a good "trend" you don't need that. It's the escape route. This is one of the reasons I came back to short this stock a second time after I made +60% return shorting the CD10 trial over the summer/fall (for statistical reasons too, albeit different ones).

Writing is on the wall and it was written by the DSMC itself.